Alkermes
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Alkermes and other ETFs, options, and stocks.About ALKS
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL.
ALKS Key Statistics
Stock Snapshot
With a market cap of 4.72B, Alkermes(ALKS) trades at $28.61. The stock has a price-to-earnings ratio of 14.15.
On 2025-11-23, Alkermes(ALKS) stock moved within a range of $28.06 to $29.00. With shares now at $28.61, the stock is trading +2.0% above its intraday low and -1.3% below the session's peak.
Trading volume for Alkermes(ALKS) stock has reached 2.03M, versus its average volume of 3.25M.
The stock's 52-week range extends from a low of $25.17 to a high of $36.45.
The stock's 52-week range extends from a low of $25.17 to a high of $36.45.
ALKS News
Ever wondered if Alkermes is a hidden gem or if it has already been discovered by the market? This deep dive will shed light on where the value may lie for curi...
H.C. Wainwright analyst Douglas Tsao has reiterated their neutral stance on ALKS stock, giving a Hold rating on November 12. TipRanks Black Friday Sale Claim 60...
Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions AI Analyst can help you make smarter investment...
Analyst ratings
81%
of 16 ratingsMore ALKS News
(RTTNews) - Alkermes plc (ALKS) and Avadel Pharmaceuticals plc (AVDL) on Wednesday said they have agreed to the terms of an increased offer under which Alkermes...
Alkermes (ALKS) and Avadel Pharmaceuticals (AVDL) announced that the companies have reached agreement on the terms of an increased recommended offer under which...
Truist raised the firm’s price target on Alkermes (ALKS) to $55 from $50 and keeps a Buy rating on the shares. Positive Vibrance-2 results materially de-risk th...